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Background: Although tacrolimus-based immunosup-
pression has made intestinal transplantation feasible, 
the risk of the requisite chronic high-dose treatment has 
inhibited the widespread use of these procedures. We 
have examined our 1990-1997 experience to determine 
whether immunomodulatory strategies to improve out-
look could be added to drug treatment. 
Study Design: Ninety-eight consecutive patients (59 
children, 39 adults) with a panoply of indications re-
ceived 104 allografts under tacrolimus-based immuno-
suppression: intestine only (n = 37); liver and intestine 
(n = 50); or multivisceral (n = 17). Of the last 42 
patients, 20 received unmodified adjunct donor bone 
marrow cells; the other 22 were contemporaneous con-
trol patients. 
Results: With a mean followup of 32 ± 26 months 
(range, 1-86 months), 12 recipients (3 intestine only, 9 
composite grafts) are alive with good nutrition beyond 
the 5-year milestone. Forty-seven (48%) of the total 
group survive bearing grafts that provide full (91%) or 
partial (9%) nutrition. Actuarial patient survival at 1 
and 5 years (72% and 48%, respectively) was similar 
with isolated intestinal and composite graft recipients, 
but the loss rate of grafts from rejection was highest with 
intestine alone. The best results were in patients be-
tween 2 and 18 years of age (68% at 5 years). Adjunct 
bone marrow did not significantly affect the incidence of 
graft rejection, B-celllymphoma, or the rate or severity 
of graft-versus-host disease. 
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Conclusions: These results demonstrate that longterm 
rehabilitation similar to that with the other kinds of 
organ allografts is achievable with all three kinds of in-
testinal transplant procedures, that the morbidity and 
mortality is still too high for their widespread applica-
tion, and that the liver is significantly but marginally 
protective of concomitantly engrafted intestine. Al-
though none of the endpoints were markedly altered by 
donor leukocyte augmentation (and chimerism) with 
bone marrow, establishment of the safety of this adjunct 
procedure opens the way to further immune modulation 
strategies that can be added to the augmentation 
protocol. (J Am Coli Surg 199U;1US:R1O-ROT~ 
© 1998 by the American College of Surgeons) 
Even with modern immunosuppressive therapies, 
clinical intestinal transplantation has not become a 
standard therapy for patients with irreversible intes-
tinal failure. 1.2 The management difficulties and un-
satisfactory longterm outcome have stemmed largely 
from the inability to completely control rejection 
without resorting to chronic heavy immunosuppres-
sion. All too often, the consequence of efforts to pre-
vent graft loss has been lethal infection, which has 
been the leading cause of death. 1.2 In previous re-
ports we identified three major immunologic risk 
factors: high blood tacrolimus levels, high-dose ste-
roid requirements, and the need for adjunct OKT3 
(antilymphoid) therapy.l In order to lower the im-
munosuppressant requirements, we declared a I-year 
moratorium in 1994, pending the results of extensive 
clarifYing investigations by Murase and associates3 in 
rats. 
When the program reopened, two changes in 
management strategy were instituted. One was an 
attempt ro avoid. when possible, the transplantation 
of organs from cytomegalovirus (CMV-positive) do-
nors to CMV-negative recipients. The other change 
was to give perioperative adjunct donor bone marrow 
when this was available, in order ro take advantage of 
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Table 1. Clinical Features of Intestinal Allograft Recipients 
Total no. of patients 
Children I adults 
Age (y) 
Children' 
Adults 
Male/female 
Duration ofTPN (mo) 
Total bilirubin (mgldL)* 
No. of abdominal operations* 
Operative time (h)* 
No. of allografts 
Cold ischemia time (h)* 
HLA (-A, -B, -DR) mismatch 
Positive cross-match 
Bone marrow augmentation 
Followup (mo) 
'p < 0.05. 
HLA. human leukocyte antigen; TPN. total parenteral nutrition. 
Isolated 
intestine 
35 
16119 
8±5 
36 ± 11 
16/19 
53 ± 47 
1.2 ± 0.7 
5.1 ± 4.3 
12 ± 4 
37 
7±2 
4.5 ± 1.2 
3 (8%) 
8 (22%) 
23 ± 21 
the more tolerogenic profile of bone marrow cells 
compared to that of the intestinal passenger 
leukocytes.3-6 
We report here our overaliiongterm results with 
104 consecutive intestinal transplantations in 98 pa-
tients. The small bowel was engrafted alone, or as 
part of a multivisceral complex, before and after the 
moratorium. Of the 42 recipients in the later period, 
20 were infused with bone marrow, the distinction 
from the other 22 being the willingness of the donor 
family to permit the extra procurement procedure. 
METHODS 
Case material 
Recipient. Case accrual was between May 2, 
1990 and August 11, 1997, during which 98 patients 
received 104 intestinal grafts: 35 alone. 48 with a 
liver, and 15 as part of a multivisceral graft. Of the 6 
retransplantations, 2 were isolated intestine and 4 
were liver-intestine or multivisceral. Children (0.5-
16.8 years) oumumbered adults (18-58 years), and 
gender distribution was nearly equal. Other demo-
graphic and clinical features are summarized in Table 1. 
The causes of intestinal failure are listed in Table 2. 
Composite 
graft Total 
63 98 
43/20 59/39 
4±4 5±5 
32 ± 9 34 ± 10 
34/29 50/48 
39 ± 41 44 ± 43 
17.4 ± 14 12 ± 14 
2.7 ± 2.2 3.6 ± 3.3 
15 ± 4 14 ± 4 
67 104 
9±3 8±3 
4.7 ± 1.1 4.6 ± 1.1 
10 (15%) 13 (13%) 
12 (18%) 20 (19%) 
24 ± 26 24 ± 24 
Short gut syndrome was the most common (n = 78), 
with a variety of causes: predominandy thrombotic dis-
orders, Crohn's disease, and trauma in adults and 
mosdy volvulus, gastroschisis, necrotizing enterocolitis, 
and intestinal atresia in children. 
Interestingly, three of the pediatric patients had 
undergone liver replacement 4-10 years before intes-
tinal transplantation. One of these is a 17 -year-old 
boy who developed short gut syndrome because of 
midgut volvulus at age 4 and was placed on total 
parenteral nutrition (TPN). At age 13, he received a 
liver allograft at another transplant center because of 
TPN-induced cholestatic liver failure. The hepatic 
allograft was subsequeiltly destroyed by TPN and the 
patient was referred for combined liver-intestine 
transplantation. The second patient had pseudo-
obstruction after birth that was not diagnosed at the 
time of his liver transplantation for biliary atresia. 
The third patient developed short gut syndrome 10 
years after his liver transplantation after extensive re-
section of the small bowel volvulus. 
All 35 recipients of 37 intestine-only grafts were 
suffering from frequent central line sepsis, vanishing 
central venous access, and variable but usually minor 
Table 2. Causes of Intestinal Failure and Indications for Transplantation 
Isolated intestine Composite graft Total 
n % n % n % 
Shorr gut syndrome 28 80 50 79 78 80 
Dysmotiliry syndrome 4 11 7 11 11 11 
Intesrinal neoplasm' 2 6 4 6 6 6 
Enterocyre dysfunction 3 2 3 3 3 
·Dcsmold. polyposis. ilnd gastrinoma. 
!I .. 
I 
I 
i 
, 
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biochemical evidence of nonicteric hepatic dysfunc-
tion. These patients had undergone an average of 5.1 
previous operations. Forty-six (73%) of the 63 recip-
ients of 67 composite allografts (multivisceral or liver-
intestine) were United Network of Organ Sharing sta-
rus I (intensive care unit [ICU] bound), or II 
(permanently hospital bound). 
Of the 15 multivisceral grafts, 13 included the 
liver; the liver was removed from the other 2 grafts 
and given to other patients. All 48 liver-intestine re-
cipients and the 13 whose multivisceral grafts in-
cluded liver had advanced hepatic disease (mean bil-
irubin > 17 mg/ 1 00 mL) that was TPN induced in 
most cases. Ischemia of the upper abdominal organs 
(adults) and diffuse irreversible gastrointestinal dis-
ease involving the foregut (mostly children) were the 
usual reasons for choosing multivisceral in preference 
to liver-intestine replacement. 
The mean followup to September 8, 1997 is 
24 ::!: 24 months (range, 1.0-86 months) for the 
total group, and 32 ± 26 months (range, 1-86 
months) for 47 current survivors with grafts in place. 
Twelve of these recipients (three isolated intestine, 
nine composite) have had functional grafts for more 
than 5 years. 
Donor. The grafts were all obtained from ABO 
blood type-identical cadaveric donors. Human leu-
kocyte antigen (HLA) matching was random and 
uniformly poor (Table 1), with no examples of zero 
-A, -B, -DR mismatches. The lymphocytotoxic 
cross-match was positive after dithiothreitol treat-
ment in 13 patients (Table 1). Because of the re-
ported adverse effect of positive donor CMV serol-
ogy on outcome, 1.7 attempts were made in the recent 
cases to avoid using CMV-positive intestinal donors 
for CMV-negative recipients. particularly those wait-
ing for intestine-only transplantation. 
Operative procedure 
Donor. Management policies and retrieval oper-
ations have been described previously.8-lo No at-
tempts were made to modulate the graft immuno-
logic tissue by donor or bowel irradiation. 
antilymphoid antibody treatment. or other modali-
ties during intact donor circulation or subsequently. 
The University of Wisconsin solution was used for 
graft preservation in all but the first case, and the cold 
ischemia time ranged from 2.8 to 17 hours (Table 1). 
In two donors. both the pancreas and intestine were 
harvested en bloc and separated on the back table for 
twO different recipients. The emeric and celiac gan-
Figure 1. Composite liver and intestinal graft with preservation of 
the duodenum in continuity with the graft jejunum and hepatic 
biliary system. Note transection of the pancreas to the right of the 
portal vein with preservation of the pancreatoduodenal arterial and 
venous arcade. The technique (used in four cases) reduces the time 
of the recipient operation and avoids the potential risks of biliary 
reconstruction. 
glia have been preserved for the past 16 grafts in an 
attempt to reduce postoperative graft dysmotility.ll 
In the four most recent combined liver-intestinal 
allografts. the standard technique has been modified, 
with the harvest of the graft duodenum in continuity 
with the jejunum and allograft biliary system (Fig. 1). 
In one of these grafts. the left lateral hepatic segment 
was successfully used after an in situ split was per-
formed to overcome a donor/recipient size mismatch 
in an ICU-bound 3-year-old child with hepatointes-
tinal failure. In this case. the vascular and biliary 
structures of the left lateral liver segment were main-
tained in continuity with the intestine. 
Recipient. The principles and various modifica-
tions of the three generic intestinal transplantation 
procedures (intestine. liver-intestine. and multivis-
ceral) have been reported elsewhere. 8.10.12-17 The ve-
nous outflow from 28 (76%) of the 37 isolated intes-
tinal grafts was drained into the recipient portal 
system; and in the other 9. it was directed into [he 
inferior vena cava. When combined liver-intestinal 
transplantation was performed (n = 48), prelimi-
nary portocaval shunt of the native vessels was per-
formed in order to prevent porral hypertension and 
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bleeding during dissection and removal of the host 
organs. The shunt was left permanently in 33 (69%) 
of the operations, but in the remaining 15 it was 
disconnected after graft revascularization and the 
host portal vein was anastomosed to the side of the 
allograft portal vein. 
A segment oflarge intestine was included with 32 
(31 %) of the allografts: 12 of the 37 (32%) isolated 
intestines, and 20 of the 67 (30%) composite grafts. 
Inclusion of the colon was abandoned after 1994 
because it appeared to increase mortality.! 
Management and monitoring 
Nutrition. The conversion from parenteral to 
enteral alimentation was highly variable, necessitat-
ing flexible and complex metabolic and surgical 
management, which differed among the three co-
horts of intestinal allograft recipients. This has been 
comprehensively described elsewhere. 12,15,18,19 Re-
sumption of oral diet was later in the composite graft 
recipients than in those receiving intestine-only. 
Immunosuppression. Therapy was based on ta-
crolimus and prednisone. Adjunct prostaglandin El 
was infused intravenously during the early postopera-
tive period to all but the first eight recipients. In the last 
23 patients (10 isolated intestine, 13 composite), cyclo-
phosphamide (cyroxan) was given at a dose of2-3 mg! 
kglday for 4 weeks and then switched to mycopheno-
late mofetil (15-30 mg!kglday) or azathioprine. In a 
few cases, azathioprine was given as a third drug from 
the outset. Episodes of rejection were treated with ad-
justments of tacrolimus dose or supplemental pred-
nisone (or both), and, if necessary, OKT3. Upward 
dose adjustments of mycophenolate mofetil, azathio-
Table 3. Clinical Features of Bone Marrow-Augmented 
Intestinal Recipients and Control Patients 
Children/ adult 
Male/temale 
Allograft 
Intestine 
Composite 
Duration ofTPN (mo) 
Total bilirubin (mg/dL) 
No. of abdominal operations 
Operative time (h) 
Cold ischemia time (h) 
HLA (-A, -B, -DR) mismatch 
Positive CYtotoxic cross-match 
Followup' (mo) 
8M -augmented 
group 
(n = 20) 
13/7 
9111 
8 (40%) 
12(60%) 
59 ± 53 
17 ± 15 
5 ± 4 
14 ± 6 
9.7 ± 2.8 
4.4 ± 1.1 
2 (10%) 
U ± 12 
BM. bone: marrow; TPN. total paremeral nutrition. 
Control 
group 
(n = 22) 
16/6 
16/6 
7 (32%) 
1'5 (68%) 
49 ± 49 
21 ± 16 
4±3 
14 ± 4 
9.2 ± 3.0 
4.4 ± 1.1 
6 (27%) 
13 ± 11 
prine, or steroids were frequently needed to compensate 
for tacrolimus dose reductions mandated by 
racrolimus-related adverse effects. 12,15,18 
Bone marrow augmentation. With informed 
consent from both donor and recipient families, 
bone. marrow (BM) cells were recovered from the 
intestinal donor, prepared, and infused intravenously 
into the recipient perioperatively. Intestinal recipi-
ents, for whom permission for BM harvest could not 
be obtained, were considered to be prospective con-
temporaneous control patients. The preparation of 
the "unpurged" cell infusate from donor thoraco-
lumbar vertebrae has been described elsewhere.20-22 
A single infusion of 3-5 X 108 cells/kg body weight 
was given for 20 minutes, 2"':'12 hours after revascu-
larization of the intestinal graft (n = 20). All of the 
bowel transplantations were primary except in one 
patient of the BM group. Except for a disparity in 
gender distribution, the two cohorts were similar 
(Table 3). 
Chimerism. The presence of donor cells in the 
recipient's peripheral blood mononuclear cells were 
evaluated serially after transplantation by either flow 
cytometry or polymerase chain reaction (PCR). 
Monoclonal antibodies specific for donor HLA class 
I molecules were used for single color immunofluo-
rescence analysis, which was performed using EPICS 
Elite flow cytometry (Coulter Corp., Hialeah, FL). 
The procedure used for cell staining has been de-
tailed elsewhere.20 For PCR analysis. primers specific 
for donor HLA class II allele or else the SRY region of 
the Y chromosome (in male donors to female recip-
ients) were used. 
Rejection surveillance. Acute rejection was diag-
nosed by histopathologic studies of random and en-
doscopically guided multiple mucosal biopsies, usu-
ally of the ileum. A new rejecrion episode was defined 
by documentation of new histologic changes. 
Chronic rejection was diagnosed by full-thickness 
histologic examination of rhe enterectomy speci-
mens. The criteria adopted for diagnosis of acute and 
chronic rejection have been described elsewhere.23 A 
total of 4,472 gastrointestinal allograft biopsies 
(4,093 small bowel. 272 colon. and 107 stomach), 
and 258 liver allograft biopsies were obtained during 
the study period and were examined by a single trans-
plant pathologist. All of the liver rejection episodes 
tabulated here were biochemically suspected, histo-
logically documented. and medically treated. 
Graft-versus-host disease surveillance. Suspi-
cious skin or gastrointestinal lesions were biopsied 
and studied by conventional histopathologic meth-
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ods. Immunohistologic staining for donor-specific 
HLA antigens, and in situ hybridization technique 
using the Y chromosome-specific probe permitted 
skin chimerism to be ruled in or our.24-26 Other tar-
get organs of graft-versus-host disease (GVHD) 
(lungs, bone marrow, and liver, when relevant) were 
evaluated repetitively. 
Infection. Protocols for prophylactic and active 
treatment of viral, bacterial, and fungal infec-
tions15.27 were adopted from those developed for 
liver transplantation. During the last half of the se-
ries, the newly developed technique of semiquantita-
tive PCR assay of Epstein-Barr virus (EBV) in the 
peripheral blood was routinely used for early detec-
tion, and monitoring of EBV viremia, which fore-
warns of the development of B-cell lymphoma. 
CMV-specific hyperimmune globulin (Cytogam) 
was added to the early postoperative antiviral pro-
phylaxis and used as an adjunct to ganciclovir for 
active EBV and CMV diseases.27 
Statistical analysis. Data were collected for the 
total group, pooled at first, and then stratified ac-
cording to the type of transplanted graft. Data anal-
yses in the patients treated with adjunct BM focused 
on comparison of results with those of contempora-
neous control patients. Continuous variables were 
presented as mean ::!:: standard deviation (SD), and 
categorical data as proportions. Differences in group 
means were tested using the standard two-tailed sam-
ple t-test and differences in proportions by Fisher's 
exact test. The two modified multivisceral grafts 
(without a liver) were excluded from any compara-
tive analysis between isolated intestine and compos-
ite grafts. 
Patient and graft survival curves were generated 
using the Kaplan-Meier method,28 and group com-
parisons were done using the log-rank test. 29.30 The 
isolated intestinal recipients in whom the allograft 
was removed, and immunosuppression was stopped, 
were censored at the time of their hospital discharge. 
The cumulative risk of rejection and graft loss ftom 
rejection were estimated using the Kaplan-Meier 
method. 
Risk factors for mortality, graft loss, and morbid-
ity were analyzed using Cox's proportional hazards 
mode!.3! Factors independently associated with Out-
comes were identified using a stepwise (backward 
elimination method) procedure. 
The mean values for the tacrolimus and steroid 
doses and rhe measured 12-hour tacrolimus whole 
blood trough levels were collected for each patient at 
7 days, 30 days. 90 days. 6 months. 12 months. and 
every year after. The crough plasma levels that were 
100 
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Figure 2. Kaplan-Meier patienr and graft survival fates for the total 
patient group. 
obtained early in the study were converted to whole 
blood values by multiplying each plasma level by a 
factor of 10.32 The values were pooled for the BM-
augmented and control cohorts and the mean 
value ::!:: standard error calculated. 
The dependence between recurrent intestinal re-
jection and graft failure (ie, death or retransplanta-
cion) and mortality was examined by incorporating 
recurrent events as time-dependent covariates, in 
Cox's proportional hazards model. 33 The effect of 
recurrent rejection was adjusted for the various rele-
vant factors. 
All analyses were performed using SPSS (SPSS, 
Inc., Chicago, IL) and S-Plus (Stat Sci Division, Se-
attle, WA) for Windows software. 
RESULTS 
Patient survival 
Overall. Current survivors who are still bearing 
their grafts (n = 47) have been followed up for 32 ::!:: 
26 months (range, 1-86 months); 2 are successful 
retransplant recipients (one isolated intestine, and 
one combined liver-intestine). Fifteen recipients sur-
vived more than 5 years. Kaplan-Meier survival rate 
is 72% at 1 year and 48% at 5 years (Fig. 2). Most of 
the deaths occurred during the tlrst 30 postoperative 
months. 
The survival rate was similar among the three 
different types of transplantation (p = 0.6). Of the 
seven isolated intestinal recipients who were cen-
sored posthospitalization following graft enterec-
tomy. five died later ofTPN-related complications. 
The other twO are alive and at home on TPN. 
The ettect of age on survival is shown in Figure 3. 
Patients 2 years and younger had a high early post-
~ 
t 
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Figure 4. Patient survival rates for the bone marrow-augmented 
and control groups. 
operative mortality, with technical failure being the 
leading cause of death (50%). The best results were in 
patients between 2 and 17 years of age, in whom the 
5-year cumulative survival rate was 68%. 
BM augmentation study. The 6-month and 
2-year patient survival rate in the study group was 
89% and 72%, respectively (Fig. 4), compared with 
77% and 57%, respectively, in the control group. 
Importantly, no mortality occurred beyond the first 
postoperative year in the BM group. Fourteen pa-
tients in each cohort are currently alive bearing func-
tioning grafts, all with nutritional autonomy. 
The time and cause of death in both groups are 
listed in Table 4. Of interest, only one of the four 
deaths in the experimental group was from a classic 
complication of immunosuppression, versus four of 
the seven deaths in the control group plus a fifth from 
intractable rejection. This did not correlate with a 
greater dependence on high dose prednisone or ta-
crolimus during the dangerous early posmansplant 
~ ~ 
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Figure 3. Patient survival according to recipient age, 
period, compared with the requirements in the BM-
augmented cohort (Fig. 5). 
The beginning dosages of the multiple agents 
were similar in both groups, except for an arbitrarily 
higher rate of cyclophosphamide use for induction in 
the control patients (61 % versus 41 %). It was note-
worthy, however, that the oral tacrolimus doses re-
quired to maintain equivalent blood level were lower 
in the BM cohort (Fig. 5). In addition, OKT3 was 
thought necessary to control rejection in only four 
(20%) of the BM group versus nine (41%) of the 
control cohort. 
Graft survival 
Overall survival. The estimated 1- and 5-year 
survival (n = 104) was 64% and 40% (Fig. 2), with 
no difference between the intestine-alone and com-
posite grafts (p = 0.97). Examination of the survival 
curves, however, showed a crossing oflines between 2 
and 3 years whereby the superior earlier survival of 
the isolated intestinal grafts was lost (Fig. 6). This 
correlated with a higher cumulative risk of graft loss 
from rejection (see later). 
BM augmentation study. Survival of the BM-
augmented grafts was 75% at 6 months, and 61 % at 
2 years compared with 77% and 52% in the control 
group (Fig. 7). It should be noted, however, that two 
of the graft losses in the experimental group were 
unequivocally caused by management or technical 
errors (one example each). One of these patients is 
alive after retransplantation; the other died of liver 
failure more than 2 years after resuming TPN. 
One (5%) of the BM-augmented, and 2 (9%) of 
the control grafts were lost because of acute rejection. 
Graftectomy and retransplantation 
Intestine alone. Thirteen graft enterectomies 
were performed in 12 recipients (8 adults, 4 chil-
dren), 9-840 days from the time of transplantation 
(median, 285 days) because of refractory acute (n = 
6) or chronic rejection (n = 2), B-cell lymphoma 
(n = 2), neuronal demyelinization (n = 1), CMV 
retinitis/enteritis (n = 1), or pseudomonas pneumo-
nia (n = O . 
Although retransplantation was done in three 
isolated intestine recipients, using intestine-only 
(n = 2) or a muIrivisceral graft (n = 1) 16,61, and 
340 days after primary enterectomy, two of the recip-
ients died 20 days and 5 months later, respectively; 
the third is well 32 months after the second intestine-
only retransplantation. Of the other nine patients 
whose intestine-only grafts were excised, two died of 
sepsis after their enterectomies, five died later of 
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Table 4. Time and Cause of Death Among Bone Marrow-Augmented Intestinal Recipients and Control Patients 
Time 
Pt. No. Graft (days) Cause 
BM-augmented (n = 20) 
LlI Hepatic artery thrombosis 1 19 
2 LIl 60 Pancreatitis and gastric bleeding 
3 MV 203 Aspergillosis 
4 LlI 228 Acute dissection of ascending thoracic aorta 
Control (n = 22) 
1 LlI 6 Arterial thrombosis 
2 LlI 51 Cerebral infarction* 
3 MV 58 Acute rejection 
4 I 119 Aspergillosis 
5 LIT 119 Aspergillosis 
6 LlI 27 CMV/B-lymphoma 
7 UI 602 Aspergillosis 
'Intraoperative cardiac arrest. 
Pt. No .• patient number; 8M, bone marrow; UI. liver-intestine; MY, multivisceral; I, intestine; CMY, cytomegalovirus. 
TPN-related complications, and two are alive 28 and 
40 months after enterectomy. 
Composite grafts. Two of the 48 liver-intestine 
recipients had their failing primary grafts removed 
and replaced at 30 and 59 days. A third underwent 
multivisceral transplantation 455 days after the pri-
1 40 
EfF~ 30 ::l ~ E"8...J 
.- E easc, 
u E 20 t!~-0 
.s:: 
~ 10 
mary liver-intestine procedure, and a fourth had at-
tempted replacement of an infarcted liver but not the 
intestine, which still functioned. The only survivor, 
who is well 3 months after retransplantation, was the 
one with intervention at 30 days. The two others 
whose entire grafts were removed died after 1.5 and 2 
---- Control 
-- BM-Augmented 
o~----~----~-----~-----~-----~-----~---
0.7 
3l 0.6 
U~ 0.5 
~~ 0.4 e~ 0.3 
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Figure 5. Tacrolimus whole blood trough levels and racrolimus and prednisone doses in rhe bone marrow (BM)-
augmented and control groups. IV, intravenous; PO, oral. 
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Figure 6. Allograft: survival of the intestine-only or as part of a 
composite graft that contained liver. 
months from intractable acute rejection and B-cell 
lymphoma. respectively. 
No multivisceral retransplantations were 
performed. 
Causes of Death 
In addition to the foregoing 13 deaths. 36 pa-
tients died with their primary graft in place. The 
primary causes of these 36 mortalities were infection 
(n = 15), technical/management errors (n = 8), 
B-cell lymphoma (n = 6), rejection (n = 5). and 
other (n = 2). All of the technical-, lymphoma-, and 
rejection-related deaths were among the composite 
allograft recipients. At the time of their death, 18 
(50%) of these 36 recipients had already achieved 
and maintained full nutritional autonomy, and 6 
(17%) had partially functioning intestinal allografts. 
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Figure 7. Graft: survival rates for the bone marrow-augmented and 
conrrol groups. 
Risk Factors 
We previously reported six risk factors: high ta-
crolimus blood level, steroid bolus therapy, use of 
OKT3. length of operation, CMV disease, and in-
clusion of a segment of colon with the graft. I With 
univariate and multivariate analyses, other important 
ones have emerged. Both patient and graft survival 
were significantly influenced by number of intestinal 
rejection episodes, development of B-cell lym-
phoma, cold ischemia time, number of previous ab-
dominal operations, and male donor to male 
recipient. 
Rejection 
Overall. Acute rejection severe enough to be 
treated was diagnosed by histologic findings in 97 
(93%) of the 104 intestinal allografts; most were 
graded mild to moderate. The degree ofHLA antigen 
mismatch did not affect the incidence (p = 0.9) nor 
the frequency of rejection (p = 0.6). More than 50% 
of the episodes occurred within the first 90 days after 
transplantation. Only 14% were diagnosed and 
treated beyond the second year after transplantation. 
The incidence of intestinal rejection was similar 
for both positive and negative lymphocyrotoxic 
cross-match grafts (p = 0.3). The mean number of 
episodes, however. was significantly higher in posi-
tive cross-match grafts (5.4 ± 2.6) compared with 
those who had negative cross-match grafts (3.3 ± 3) 
(p = 0.03). . 
The isolated intestine had a significantly higher 
incidence of rejection (92%) compared with intes-
tine contained in a composite graft (66%) during the 
first 30 postoperative days (p = 0.004), a gap that 
narrowed during the rest of the first postoperative 
year but remained significant (p = 0.001) (Fig. 8). 
Although the cumulative rejection rate of intestine 
contained in a composite graft approached that of 
isolated intestine (Fig. 8), the rate of graft loss from 
rejection was less than half (Fig. 9). 
The median postoperative time to the first epi-
sode of intestinal rejection was 9 days for the isolated 
intestine, and 19 days for the composite grafts (p = 
0.0001). OKT3 was required to treat steroid-
resistant rejection in 20 (54%) of the isolated intes-
tine, and 15 (23%) of the composite grafts (p = 
0.002). Systemic venous drainage of the allografted 
intestine did not increase the risk of rejection or graft 
loss (p = 0.7). 
In the recipients of composite grafts. the inci-
dence of liver rejection was less than half of that in 
the intestine (Fig. 10). The median time to diagnosis 
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Figure 8. Cumulative risk of intestinal rejection for the isolated 
intestine and composite grafts that contained liver. 
of the first episode was 58 days, and the mean num-
ber of episodes in all cases was 0.78 :± 1.5 days. 
Eleven (34%) of the 32 intestinal allografts, 
which included colon, showed histologic evidence of 
colonic rejection at some time. Two (12%) of the 
multivisceral grafts had histologically proved gastric 
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Figure 9. Cumulative risk of graft loss from rejection in the 
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Figure 10. Cumulative risk of both intestinal and hepatic rejection 
in the composite visceral allografts. 
rejection, and another two (12%) had pancreatic 
rejection. 
Acute vascular rejection was histologically docu-
mented in three of the isolated intestinal allografts, 
two of which were from strongly positive lymphocy-
totoxic cross-matched donors. One positive and one 
negative cross-match graft eventually were lost to re-
jection; the third fully recovered (Fig. 11). 
Chronic rejection was diagnosed in three enter-
ectomy specimens for an incidence with isolated in-
testinal transplantation of 8%. The only example of 
chronic rejection of a composite graft was in a patient 
whose donor was strongly cross-match positive; both 
the intestine and liver were affected, and the recipient 
died of combined hepatic and intestinal failure. Be-
cause the diagnosis of chronic rejection requires a 
transmural specimen that is not deliberately obtained 
in biopsies, the incidence of chronic rejection un-
doubtedly was grossly underestimated. 
BM augmentation study. Although the inci-
dence of acute rejection during the first postoperative 
month was higher (p = 0.2) in the BM cohort (85%) 
compared with the control patients (64%), the over-
all incidence, frequency, and median time of onset of 
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Figure 11. Acute vascular rejection of positive cross-match isolated intestinal graft. (A) This biopsy specimen obtained 4 hours after 
transplantation shows typical changes of acute vascular rejection. with pronounced hemorrhage and congestion obscuring the lamina 
propria. The villi, although intact, are shortened, and the surface epithelium is focally lost. Inflammatory infiltration is minimal. Small 
arterioles demonstrated endothelial hypertrophy, mural thickening, platelet thrombi, and focally spa.rse neutrophil infiltration (in-
sert). (B) Fifteen days after transplantation and after treatment with steroids and OKT3, the mucosa displays prominent evidence of 
mucosal regeneration. The crypts are irregular, branched, and lined by hyperplastic epithelium with crowded, pseudostratified cells. 
Toward the luminal surface, early villus formation can be appreciated. The lamina propria retains a mild component of inflammatory 
cells, primarily small lymphocytes and scattered plasma cells. 
the first episode were similar in the two groups. 
OKT3 was used to control rejection in four (20%) of 
the BM recipients, and nine (41%) of the control 
patients (p =0.2). 
Viral infections 
CMV disease. Thirty-five (36%) of the 98 recip-
ients had at least one episode of clinically significant 
new or reactivated CMV infection, with a median 
onset of 65 days after transplantation (range, 10-276 
days). The incidence according to the donor and re-
cipient CMV serologic status was 68% for positive to 
negative; 54% for positive to positive; 36% for neg-
ative to positive; and 8% for negative to negative. 
The difference in risk of CMV disease in adults 
(44%) and children (31 %) was not significant (p = 
0.2). There was no difference in the incidence and 
onset of CMV disease between isolated and compos-
ite graft recipients, or during the BM augmentation 
trial between patients given the adjunct treatment 
(35%) and control patients (44%) (p = 0.8). 
EBV-associated b-cell lymphoma. Twenty pa-
tients (20%) developed posttransplant EBV-related 
B-cell lymphoma at a median time of 8.7 months 
after transplantation (range, 1.1-61.8 months), in-
volving both native and transplanted organs. The 
abnormality was found in the autopsy specimens of 
four of these recipients. Children (27%) were at a 
significantly higher risk than adults (11 %) (p = 
0.02). The disease was lethal in 9 (45%) of the 20 
patients (7 children, 2 adults). 
The multivisceral patients (33%) were more 
prone than the recipients of liver-intestine (21 %), 
and intestine-only (11 %) grafts (p = 0.2). In the BM 
augmentation trial period, the incidence was 2 
(10%) of20 in the experimental group and 4 (18%) 
of22 in the control patients (p = 0.60). 
Using univariate and multivariate analyses, 
young age, type of intestinal graft (multivisceral), 
and recipient splenectomy were the three significant 
risk factors for the development ofB-celllymphoma. 
Graft-versus-host disease 
Skin changes suspicious for GVHD were ob-
served in 11 patients, but histologically verified in 
only 5 (5%). Two of the 5 had received intestine-only 
and the other 3 composite grafts. The GVHD was 
lethal in only one patient. a previously reported 
child34 with preexisting 19A deficiency who received 
a liver-intestine graft. One patient. an adult recipient 
of a multivisceral graft. developed chronic GVHD, 
which was diagnosed by biopsy of the buccal mucosa. 
This patient eventually died of disseminated B-cell 
lymphoma. with the chronic GVHD still active. 
The disease was self-limited in the other three 
patients, one of whom had received adjunct BM. The 
latter patient developed a mild skin rash 188 days 
after liver-intestine transplantation. The disease was 
easily controlled in this and another intestine-only 
recipient by an increase in the daily tacrolimus and 
steroid doses. The third patient experienced transient 
GVHD 6 days after graft enterectomy and with-
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Figure 12. (A-D) Serial determination of donor cell chimerism in the peripheral blood of a bone marrow-augmented 
small bowel recipient for up to 358 days after transplantation. (D) For the determination of chimerism, FITC-
conjugated monoclonal antibody specific for donor HlA class I (anti-S8) was used. (B) Cells stained with fluorochrome-
conjugated, irrelevant. ootype-matched (IgG2J monoclonal antibody and (C) those obtained from the cadaveric donor were 
used as negative and positive controls, respectively. (A) Orthogonal and side scatter profiles were used to establish gates for 
lymphocyte subpopuiation, analysis of which was done using an EPICS Elite flow cytometer (Coulter, Hialeah, FL). As evident 
in Figure 0,0.90/0-1.6% of donor cell chimerism was present in the peripheral blood of this recipient and has remained 
relatively stable for up to 1 year after transplantation. SSC, side scatter channel; FSC, forward scatter channel; HlA, human 
leukocyte antigen; PGE, percentage gated events; POD, postoperative day. 
drawal of immunosuppression because of the devel-
opment ofB-celllymphoma. 
published previously for other BM-augmented organ 
transplant recipients.35 
Chimerism 
The nonavailabiliry of either an appropriate 
monoclonal antibody or the donor-specific primer 
precluded the analysis of chimerism in four BM-
augmented and seven control patients. Using these 
techniques, however, at their most recent followup, 
16 (100%) of 16 study and 12 (80%) of 15 control 
patients had evidence for the presence of donor cell 
chimerism. Additionally, when followed up serially 
after transplantation, BM-augmented recipients had 
much higher levels of donor cell chimerism than con-
trol patients (Fig. 12); an observation similar to that 
Longterm rehabilitation 
Forty-three (91 %) of the 47 current survivors are 
home and completely offTPN, with full nutritional 
autonomy. Two of the remaining four recipients re-
quire home parenteral nutrition because of chronic 
graft dysmotility. The other two patients are receiv-
ing partial intravenous nutritional support while re-
covering from a recent episode of severe intestinal 
rejection. No attempts have been made to date to 
electively reduce or wean any of the intestinal recip-
~entsI including the BM-augmented recipients, off 
Immunosuppression. 
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DISCUSSION 
Empirical progress in organ transplantation de-
pended for 30 years on a search for more potent 
baseline immunosuppressants, without understand-
ing the basis for the prototypic immunologic con-
frontation (rejectioh) and involution ("graft accep-
tance") that was first observed in kidney recipients 
treated with azathioprine and prednisone.36 The ad-
vent of cyclosporine elevated the expectations with 
transplantation of most organs to the level of patient 
service, but the resulting revolution largely bypassed 
the intestine. Nevertheless, prolonged alimentary 
nutrition (ie, > 6 months) from human intestine, 
d f · aft 37-40 transplante as a component 0 composite gr s 
or alone41 ,42 was achieved for the first time using 
cyclosporine-based immunosuppression between 
November 1987 and the end of 1989. These were 
rare cases, however, and only the pediatric patient of 
Goulet and associates,42 who received an isolated 
neonatal intestine, remains alive. 
With the clinical introduction of tacrolimus in 
198943 and the demonstration of superior clinical 
results with a variety of organ allografts, compared 
with results previously with cyclosporine,44 interest 
was intensified in intestinal transplantation. After 
preclinical studies showed the superiority of the drug 
in animal models ofintestine-alone and multivisceral 
transplantation,45-48 large-scale trials of intestinal 
and composite visceral transplantation were under-
taken in 1990.1,12-15 The present report accounts for 
all cases accrued since then at the University of Pitts-
burgh, divided into two cohorts, three-fifths before 
and two-fifths after the I-year moratorium of 1994. 
With 12 patients from the first period in good 
nutritional condition beyond the 5-year posttrans-
plant milestone, there is little residual doubt about 
the feasibility, if not the reliability, of all three bowel 
transplant procedures. It has also become evident 
from data reported previously,1.15 and now, that the 
management strategy must be modified further be-
fore these operations find a respected place in the 
surgical armamentarium. The observations described 
here, combined with major advances in transplanta-
tion immunology (see later), provide insight into 
how this may be done safely. 
During the same 1990-1997 period of the intes-
tinal transplant case accrual, an explanation applica-
ble to all organs evolved for the previously enigmatic 
ability to transplant HLA-incompatible allografts. 
This began with the discovery that the hematolym-
phopoietic cells ofBM origin (passenger leukocytes), 
which are normal constituents of all organs, migrate 
an'd engraft peripherally after successful transplanta-
tion.24-26.49 Until this time, clinical trials of trans-
plantation of the leukocyte-rich intes~ine had been 
inhibited by the fear that the lymphOid cells would 
cause GVHD, such as occurs after conventional BM 
transplantation from HLA mismatched donors to 
cytoablated recipients. 
As a result of this anxiety, many experimental 
studies of intestinal transplantation until the late 
1980s were designed for the pretransplant destruc-
tion of the lymphoid-rich passenger leukocytes. 50-52 
It became clear that a mutual nullification of the 
host-versus-graft (rejection) and graft-versus-host re-
actions could be expected in the immunologically 
intact recipient under conditions of immunosup-
pression that equally affect both donor and recipient 
cell populations. 53 The bidirectional induction of 
specific nonreactivity occurs primarily by a mecha-
nism of clonal exhaustion/ deletion that takes place in 
organized lymphoid centers,24,49 in the same way as 
tolerance to noncytopathic intracellular parasites (vi-
ral, bacterial, and protozoa) leads to a "carrier 
state."54 Because the exhaustion/deletion that takes 
place in organized lymphoid collections is neither 
absolute nor irreversible, its maintenance is depen-
dent on the persistence of donor leukocyte chimer-
ism that may be present in these locations at very low 
levels (microchimerism). 
In a second mechanistic analogy to infectious 
immunity, 54 the migration of passenger leukocytes 
from the graft and their replacement by those in a 
reverse traffic from the recipient suggests a second 
less quantifiable mechanistic contribution of im-
mune indifference. Because a large number of the 
cells departing the graft find their way to the skin and 
other nonlymphoid centers, immune indifference 
could be operational at the graft level or peripherally, 
or at both sites. 54 In experimental models, pure ex-
amples of immune indifference can be produced by 
pretransplant depletion of the passenger leukocytes, 
but the chimerism-dependent donor-specific toler-
ance is not thereby induced. 55-57 
These two tolerance mechanisms are generic 
with the successful engraftment of all or-
gans.24.49.53.54 It has been shown in rat experiments, 
however, that the lineage profile of passenger leuko-
cyte in intestine has inferior tolerogenic qualities (ie, 
fewer undifferentiated stem, precursor, and myeloid 
cells and more mature T and B lymphocytes than in 
BM and solid organs, especially the liver).3.58 In the 
clinical context of our intestinal transplant series, the 
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consequent protective effect on the intestine of the 
contemporaneously transplanted liver was obvious, 
and explained by the similarity of the hepatic passen-
ger leukocyte lineage profile to that of BM. The cu-
mulative risk of intestinal loss to rejection in a com-
posite graft was only one third that incurred by 
intestine that was transplanted alone (Fig. 9). 
With the information already available in 1994 
from many of the foregoing clinical and experimen-
tal investigations, it was possible to proceed with the 
trial of donor leukocyte augmentation I without the 
historically rooted fear of an increased risk ofGVHD 
that has been exemplified by the warnings of Gruess-
ner and coauthors. 59 The absence of added risk was 
evident in the results. There were no examples of 
lethal GVHD in the 20 patients treated with adjunct 
BM, and the incidence ofless significant GVHD was 
no greater than in the contemporaneous control 
group. Other possible complications ofBM augmen-
tation (eg, a greater risk of rejection or ofB-celllym-
phomas) were not seen. 
Although the trial has established the safety of 
BM augmentation, definitive evidence of efficacy is 
expected to take 5 to 10 years to be manifest, as has 
been the case with adjunct BM infusion with other 
organs.20,60 Because the time of greatest need for 
improvement is the morbidity- and mortality-ridden 
first posttransplantation months, however, we con-
sider the augmentation trial to be only the first step 
in developing an immune modulation strategy in-
volving cytoablation of the graft passenger leukocytes 
that will ameliorate the early posttransplantation 
risk. In our pretacrolimus cases of multivisceral trans-
plantation,8,37.61 this was done by treating the cadav-
eric donor with large doses of OKT3 before organ 
extirpation, followed by low-dose donor intestinal 
irradiation before or after graft revascularization. 
In these early cases, and in virtually all others 
elsewhere in which similar graft modification was 
attempted, the recipients developed lethal operative 
B-celllymphomas in the allografts and systemically. 8 
Consequently, this approach was abandoned despite 
evidence that intestinal cytoablation in experimental 
models caused a reduction in GVHD incidence and 
improved survival. 50-52 In retrospect, the lymphoma 
complication seen in patients may have been from 
the imbalance of the T-cell to B-cell population in the 
grafts caused by administration to the donors of the 
T-cell directed antilymphoid agents. 
Graft cytoreduction with relatively low doses of 
ex vivo irradiation (500-100 R), as reported by Wil-
liams and associates52 in a canine model is thought to 
proportionately reduce mature T and B cells without 
killing of stem and precursor cells and without seri-
ously damaging either the vascular or epithelial com-
ponents of the intestinal graft (Murase and cowork-
ers, unpublished observations). In experiments using 
the same GVHD-prone rat intestinal transplant 
models used originally to demonstrate the dynamics 
of passenger leukocyte traffic,3.58 a dramatic benefit 
has been demonstrated of ex vivo irradiation com-
bined with systemic donor BM cell infusion (Murase 
and coworkers, unpublished observations). Conse-
quently, we plan to bring the combined strategy of 
graft irradiation plus adjunct donor BM infusion to 
clinical trial. 
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Invited Commentary 
Rainer w.G. Gruessner, MD, phD, FACS, 
Minneapolis, Minnesota 
Intestinal transplantation has become an alterna-
tive for selected patients with irreversible intestinal 
failure and life-threatening total parenteral nutrition 
(TPN) complications. According to the Interna-
tional Intestinal Transplant Registry, I 273 intestinal 
transplants in 260 patients were reported through 
February 1997. Of those 273 transplants, 130 (48%) 
were combined liver-intestinal transplants, 113 
(41 %) were intestinal transplants alone, and only 30 
(11 %) were multivisceral transplants. For transplants 
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done since January 1, 1995, the I-year patient sur-
vival was 90% for intestinal transplants alone and 
67% for combined liver-intestinal and multivisceral 
transplants; I-year graft survival was 65% overall and 
for each of the three transplant categories. 
It is to the credit of Dr. Starzl and his team at the 
University of PittSburgh that bowel transplantation 
has become a clinical alternative for patients with 
end-stage intestinal failure and life-threatening com-
plications. They were the first to use tacrolimus for 
intestinal transplant recipients. This drug proved to 
be superior to cyclosporine for this population. Dr. 
Starzl and his team also revolutionized the field in 
many different areas, such as standardization of sur-
gical techniques for combined liver-intestinal and 
multivisceral transplants from cadaver donors, re-
finements in antimicrobial prophylaxis and treat-
ment, studies on posttransplant absorption and mo-
tiliry, and introduction of new immunomodulatory 
strategies.2 The PittSburgh series comprises, by far, 
the world's largest experience in intestinal transplan-
tation. They have led the way in this field. Their 
successes and failures made it possible for an increas-
ing number of transplant centers throughout the 
country, including ours, to perform intestinal trans-
plants. But despite Pittsburgh's impressive series, I 
would like to make a few critical comments: 
1. Dr. Stanl has repeatedly propagated the use of 
unaltered donor-specific bone marrow infusion as 
part of a primarily vascularized organ transplant. 
The Pittsburgh team has shown that simulta-
neous infusion of donor-specific bone marrow 
augments chimerism after transplantation. Dr. 
Stanl has postulated that multilineage chimerism 
ultimately would result in graft acceptance and 
longterm tolerance. But the chimeric concept (ie, 
the mutual coexistence of two genetically distinct 
components resulting in tolerance) still awaits 
convincing, reproducible confirmation in the 
clinical setting.2 In fact, chimerism is not always 
associated with a stable immunologic state; it has 
been detected in human recipients of solid organ 
transplants with rejection or graft-versus-host dis-
ease (GVHD).3 Indeed, large animal studies at 
the University of Minnesota showed that simul-
taneous infusion of unaltered donor-specific bone 
marrow in intestinal transplant recipients in-
creases the incidence of death from rejection, in-
fection, GVHD, or a combination of these three 
immunologic events.4 The rate of posttransplant 
lymphoproliferative disease in pediatric recipients 
of intestinal transplants is more than twice as high 
in the Pittsburgh series (27%) than in others5-a 
fact that nurtures my suspicion that adding unal-
tered bone marrow further complicates the post-
transplant course. Although Dr. Abu-Elmagd 
compared two more recent groups-one with, 
the other without, simultaneous donor-specific 
bone marrow infusion-this study was not ran-
domized and therefore lacks true statistical 
meanmg. 
2. From my experience, I doubt that preserving do-
nor splanchnic ganglia significantly ameliorates 
graft dysmotility. On the basis of our current un-
derstanding of neurophysiology, transection of 
the splanchnic ganglia makes complete reinnerva-
tion impossible. 
3. Rejection, infection, and GVHD remain the 
most common problems after intestinal trans-
plantation. One strategy to decrease the incidence 
of such complications is the use of living related 
donors, who could ensure better HLA matching. 
But living related intestinal transplantation has 
only rarely been attempted, because the surgical 
technique is not standardized. At the University 
of Minnesota, we have now successfully done in-
testinal transplants from living related donors, us-
ing 200 cm of ileum on a vascular pedicle com-
prising the ileocolic artery and vein. By retaining 
the most distal 20 cm of the terminal ileum in the 
donor, urine methylmalonic acid levels remain 
normal, indicating good vitamin B12 absorption. 
One of our recipients has been offTPN since his 
hospital discharge 15 months ago, has gained 20 
kg, and has had no evidence of rejection, infec-
tion, or GVHD. It appears that intestinal trans-
plants from related donors can also be life-saving 
for selected patients with end-stage intestinal fail-
ure and can be done with minimal risk to the 
donor.6 
Intestinal transplantation has come a long way. 
Dr. Abu-Elmagd and his team deserve our congratu-
lations and respect for advancing one of the last fron-
tiers in solid organ transplantation. Of all figures that 
Dr. Abu-Elmagd presented, I would like to close with 
the most impressive one: 91 % of survivors are free of 
TPN with full nutritional autonomy. Intestinal 
transplantation, if successful, not only improves 
quality of life, but also is more cost-effective than 
TPN. 
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Reply 
Kareem Abu-Elmagd, MD, PhD, FACS, Pittsburgh, 
Pennsylvania 
I appreciated Dr. Gruessner's acknowledgment 
of our work in the intestinal transplant field, and 
would like to respond to his concerns and criticisms. 
We agree with him, and have repeatedly stated (in-
cluding in my presentation), that chimerism is not 
synonymous with either stable graft acceptance or 
tolerance. It is only a necessary condition.! To at-
tribute any other view to Dr. Starzl would betray a 
flawed comprehension of what he has written. Far 
from undergoing erosion, as Dr. Gruessner implied, 
Dr. Starzl's contention that allograft acceptance de-
pends on the coexistence with the recipient immune 
system of a donor population of hematolymphopoi-
etic leukocytes has gained ground steadily since its 
proposal in 1992. 
Dr. Starzl and Professor RolfZinkernagel (Nobel 
laureate, 1996) have produced a manuscript delin-
eating precisely the tolerance mechanisms (clonal 
exhaustion/deletion, and immune indifference) that 
are driven by the chimerism.2 The unique feature of 
posmansplant chimerism is that it involves a double 
immune reaction, with " ... responses of co-existing 
donor and recipient immune cells, each to the other 
causing reciprocal clonal expansion followed by pe-
ripheral clonal deletion."! 
In the framework of the foregoing double im-
mune reaction. treatment failure for immunologic 
reasons after essentially all transplant procedures can 
be defined as uncontrollable ascendancy of one of the 
interactive arms, or sometimes both together.3 Dele-
tion of the host arm by recipient cytoablation before 
transplantation alters the balance of the two cell pop-
ulations. With transplantation of bone marrow or of 
leukocyte-rich organs (like the intestine), the domi-
nance is shifted to the graft-versus-host arm, with the 
grave risk of graft-versus-host disease. This manage-
ment strategy was what was tested in the pig study 
refered to by Dr. Gruessner in his self-citation.4 The 
results were so predictable that it is hard to explain 
why the experiments were done. 
Dr. Gruessner's comments' about the pernicious 
complication of posttransplant lymphoproliferative 
disease (PTLD) are apposite, as we have emphasized 
in the past and in our presentation today. Dr. Gruess-
ner's linkage of this complication to the bone marrow 
infusion in our cases is baseless, however. This kind of 
adjunct treatment was used in only 20 of our 98 
cases, with no increase of incidence or severity of 
PTLD compared with the contemporaneous control 
patients. Similarly, Dr. Gruessner's negativism about 
preservation of the sympathetic ganglia must be con-
sidered arbitrary, pending clarification of the relative 
effects of pre- and postganglionic denervation on the 
function of the transplanted bowel. 
It should be noted that the paucity of live donor 
intestinal transplant cases may be more from concern 
about the short- and longterm risks to the donor than 
from the lack of standardization of this relatively sim-
ple procedure, which has been reported in Japan, at 
Stanford (D. Dafoe), at Cambridge University (R. 
Calne), and elsewhere. 
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